



## Living Cell Technologies Limited

**ACN:** 104 028 042  
**ASX:** LCT  
**OTCQX:** LVCLY

### ASX ANNOUNCEMENT

## LCT extends cash runway with receipt from Vertex acquisition of Semma

---

**15 October 2019 – Sydney, Australia & Auckland, New Zealand** – LCT has received Net AUD 1,100,158 from the acquisition of Semma Therapeutics, a private company in which LCT held shares, by Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

As announced on 19 September 2019, Vertex Pharmaceuticals Incorporated (Vertex) entered into a definitive agreement to acquire Semma Therapeutics to further its development of encapsulated human stem cell derived islets as a potentially curative treatment for Type 1 diabetes, subject to certain conditions.

Semma Therapeutics had previously acquired Cytosolv Inc, a private company in which LCT obtained a shareholding in 2009, in return for the supply of encapsulated pig cells for wound healing studies.

LCT CEO, Dr Ken Taylor, said "This receipt extends LCT's cash runway and will help enable completion of our current product projects as detailed in the 2018-2019 annual report."

– Ends –

**For further information:** [www.lctglobal.com](http://www.lctglobal.com)

<p><b>At the Company:</b> Ken Taylor Chief Executive Mobile: +64 21 796 000 <a href="mailto:ktaylor@lctglobal.com">ktaylor@lctglobal.com</a></p>	<p><b>Media Contact:</b> Rachael Joel Botica Butler Raudon Partners Tel: +64 9 303 3862 Mobile: +64 21 403 504 <a href="mailto:rachaelj@botica.co.nz">rachaelj@botica.co.nz</a></p>
--	---

### About Living Cell Technologies

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which restore function using naturally occurring cells.

As well as its lead product NTCCELL, LCT is also advancing research collaborations with the University of Auckland to identify products that are candidates for out licensing to global pharmaceutical companies. Projects that have been initiated target obesity and migraine where the lead product candidates utilise patented novel peptide synthetic chemistry technology.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.

For more information visit [www.lctglobal.com](http://www.lctglobal.com) or follow @lctglobal on Twitter.

### **Forward-looking statements**

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.